1409-E2F6/SH3GL2/HMGB1 Axis in Glioblastoma Resistance
This research identifies the transcription factor E2F6 as a primary driver of temozolomide (TMZ) resistance and poor clinical outcomes in glioblastoma patients. The study reveals that E2F6 actively suppresses the expression of SH3GL2, a protein that otherwise facilitates the export of HMGB1 out of tumor cells. When E2F6 levels are high, HMGB1 is retained within the cell to assist in DNA repair, effectively shielding the cancer from chemotherapy. By experimental depletion of E2F6, researchers restored SH3GL2 levels, which triggered the secretion of HMGB1 into the extracellular space. This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.